Compounding testosterone for menopausal patients? Mark September 17 on your calendar for FDA’s public workshop examining the evidence, and the gaps, in testosterone therapy for menopausal women. The hybrid event runs 9:00am - 4:30pm ET, in person at FDA’s White Oak campus in Silver Spring, Md., or virtually. FDA is also opening a public docket (FDA-2026-N-5479) for 60 days, with comments due by October 19.
